Regioselective Versatility of Monooxygenase Reactions Catalyzed by CYP2B6 and CYP3A4: Examples with Single Substrates

  • Claudio A. Erratico
  • Anand K. Deo
  • Stelvio M. BandieraEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 851)


Hepatic microsomal cytochrome P450 (CYP) enzymes have broad and overlapping substrate specificity and catalyze a variety of monooxygenase reactions, including aliphatic and aromatic hydroxylations, N-hydroxylations, oxygenations of heteroatoms (N, S, P and I), alkene and arene epoxidations, dehalogenations, dehydrogenations and N-, O- and S-dealkylations. Individual CYP enzymes typically catalyze the oxidative metabolism of a common substrate in a regioselective and stereoselective manner. In addition, different CYP enzymes often utilize different monooxygenase reactions when oxidizing a common substrate. This review examines various oxidative reactions catalyzed by a CYP enzyme acting on a single substrate. In the first example, 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47), a halogenated aromatic environmental contaminant, was oxidatively biotransformed by human CYP2B6. Nine different metabolites of BDE-47 were produced by CYP2B6 via monooxygenase reactions that included aromatic hydroxylation, with and without an NIH-shift, dealkylation and debromination. In the second example, lithocholic acid (3α-hydroxy-5β-cholan-24-oic acid), an endogenous bile acid, served as a substrate for human CYP3A4 and yielded five different metabolites via aliphatic hydroxylation and dehydrogenation reactions.


Cytochrome P450 Human CYP2B6 Human CYP3A4 Lithocholic acid Oxidative biotransformation Polybrominated diphenyl ethers BDE-47 and BDE-99 Hydroxylated metabolites 


  1. 1.
    Burke MD, Mayer RT (1983) Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem Biol Interact 45:243–258PubMedGoogle Scholar
  2. 2.
    Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34:3337–3345PubMedGoogle Scholar
  3. 3.
    Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923–936PubMedGoogle Scholar
  4. 4.
    Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:147–204Google Scholar
  5. 5.
    Smith HS (2011) The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain 27:824–838PubMedGoogle Scholar
  6. 6.
    Kharasch ED (2000) Opioid analgesics. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, pp 297–319Google Scholar
  7. 7.
    Ryan D, Levin W (1990) Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153–239PubMedGoogle Scholar
  8. 8.
    Rendic S, Nolteernsting E, Schänzer W (1999) Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. J Chromatogr Biomed Appl 735:73–83Google Scholar
  9. 9.
    Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR (2005) Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab Dispos 33:714–718PubMedGoogle Scholar
  10. 10.
    Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17:265–270PubMedGoogle Scholar
  11. 11.
    Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54–59PubMedGoogle Scholar
  12. 12.
    Trager WF (2000) Oral anticoagulants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) Metabolic drug interactions. Lippincott Williams & Wilkins, Philadelphia, pp 403–413Google Scholar
  13. 13.
    Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253–1259PubMedGoogle Scholar
  14. 14.
    Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719–754PubMedGoogle Scholar
  15. 15.
    Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF (2004) The structure of human cytochrome P450 3A4 determined by x-ray crystallography to 2.05Å resolution. J Biol Chem 279:38091–38094PubMedGoogle Scholar
  16. 16.
    Ekroos M, Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682–13687PubMedCentralPubMedGoogle Scholar
  17. 17.
    Sevrioukova IF, Poulos TL (2010) Structure and mechanism of the complex between cytochrome P450 3A4 and ritonavir. Proc Natl Acad Sci U S A 107:18422–18427PubMedCentralPubMedGoogle Scholar
  18. 18.
    Dong D, Wu B (2012) Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44:1–17PubMedGoogle Scholar
  19. 19.
    Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906–922PubMedGoogle Scholar
  20. 20.
    Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E (2009) Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 78:184–190PubMedGoogle Scholar
  21. 21.
    Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306PubMedGoogle Scholar
  22. 22.
    Janmohamed A, Dolphin CT, Phillips IR, Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777–786PubMedGoogle Scholar
  23. 23.
    Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tract. Annu Rev Pharmacol Toxicol 43:149–173PubMedGoogle Scholar
  24. 24.
    Hoffman SM, Nelson DR, Keeney DS (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687–698PubMedGoogle Scholar
  25. 25.
    Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415PubMedGoogle Scholar
  26. 26.
    Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398–403PubMedGoogle Scholar
  27. 27.
    Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, Tomioka Y, Matsubara Y, Oda A, Hirasawa N, Hiratsuka M (2011) Functional characterization of CYP2B6 allelic variants in demethylation of antimalarian artemether. Drug Metab Dispos 39:1860–1865PubMedGoogle Scholar
  28. 28.
    Xu C, Ogburn ET, Guo Y, Dest Z (2012) Effects of the CYP2B6*6 allele on catalytic properties of inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos 40:717–725PubMedCentralPubMedGoogle Scholar
  29. 29.
    Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230PubMedGoogle Scholar
  30. 30.
    Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T (1993) Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 21:1048–1056PubMedGoogle Scholar
  31. 31.
    Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, Waxman DJ (1997) Human cytochrome P450 2B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985–992PubMedGoogle Scholar
  32. 32.
    Chang TKH, Bandiera SM, Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7–10PubMedGoogle Scholar
  33. 33.
    Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ (2000) Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 58:1441–1450PubMedGoogle Scholar
  34. 34.
    Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427–431PubMedGoogle Scholar
  35. 35.
    Wang H, Faucette SR, Gilbert D, Jolley SL, Suseyoshi T, Negishi M, LeCluyse EL (2003) Glucucorticoid receptor enhancement of pregnane X receptor mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 31:620–630PubMedGoogle Scholar
  36. 36.
    Faucette SR, Zang T-C, Moore R, Sueyoshi T, Omiechinski CJ, LeCluyse EL, Negishi M, Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72–80PubMedCentralPubMedGoogle Scholar
  37. 37.
    Washio I, Maeda M, Sugiura C, Shiga R, Yoshida M, Nonen S, Fujio Y, Azuma J (2011) Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 39:1–3PubMedGoogle Scholar
  38. 38.
    Mikyss S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122–132Google Scholar
  39. 39.
    Hodgson E, Rose RL (2007) The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol Ther 113:420–428PubMedGoogle Scholar
  40. 40.
    Wang H, Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 enzyme. Curr Drug Metab 9:598–610PubMedCentralPubMedGoogle Scholar
  41. 41.
    Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629–5637PubMedGoogle Scholar
  42. 42.
    Styles JA, Davies A, Lim CK, De Matteis F, Stanley LA, White INH, Yuan ZX, Smith LL (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15:5–9PubMedGoogle Scholar
  43. 43.
    Nakajima M, Yamamoto T, Nunoya KI, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212–1217PubMedGoogle Scholar
  44. 44.
    Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183PubMedGoogle Scholar
  45. 45.
    Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300PubMedGoogle Scholar
  46. 46.
    Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF (2009) Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10:730–753PubMedGoogle Scholar
  47. 47.
    Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041–1050PubMedGoogle Scholar
  48. 48.
    Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV (1997) Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207–214PubMedGoogle Scholar
  49. 49.
    Tang J, Cao Y, Rose RL, Brimfield AA, Dai D, Goldstein JA, Hodgson E (2001) Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos 29:1201–1204PubMedGoogle Scholar
  50. 50.
    Buratti FM, Volpe MT, Meneguz A, Vittozzi L, Testai E (2003) CYP-specific bioactivation of four organophosphorthioate pesticides by human liver microsomes. Toxicol Appl Pharmacol 186:143–154PubMedGoogle Scholar
  51. 51.
    Buratti FM, D’Aniello A, Volpe MT, Meneguz A, Testai E (2005) Malathion bioactivation in the human liver: the contribution of different cytochrome P450 isoforms. Drug Metab Dispos 33:295–302PubMedGoogle Scholar
  52. 52.
    Sams C, Cocker J, Lennard MS (2004) Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 34:861–873PubMedGoogle Scholar
  53. 53.
    Foxemberg FJ, McGarrigle BP, Knaak JB, Kostinyak PJ, Olson JR (2007) Human hepatic cytochrome P450-specific metabolism of parathion and chlorpyrifos. Drug Metab Dispos 35:189–193Google Scholar
  54. 54.
    Ellison CA (2012) Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon. Drug Metab Dispos 40:1–5PubMedCentralPubMedGoogle Scholar
  55. 55.
    Ariyoshi N, Oguri K, Koga N, Yoshimura H, Funae Y (1995) Metabolism of the highly persistent PCB congener, 2,4,5,2′,4′,5′-hexachlorobiphenyl by human CYP2B6. Biochem Biophys Res Commun 212:455–460PubMedGoogle Scholar
  56. 56.
    Stresser DM, Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P450 2B6. Drug Metab Dispos 27:517–525PubMedGoogle Scholar
  57. 57.
    Hu Y, Kupfer D (2002) Metabolism of endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab Dispos 30:1035–1042PubMedGoogle Scholar
  58. 58.
    Hu YD, Kupfer D (2002) Enantioselective metabolism of the endocrine disruptor pesticide methoxychlor by cytochromes P450 (P450s): major differences in selective enantiomer formation by various P450 isoforms. Drug Metab Dispos 30:1329–1336PubMedGoogle Scholar
  59. 59.
    Lee HK, Moon JK, Chang CH, Choi H, Park HW, Park BS, Lee HS, Hwang EC, Lee YD, Liu KH, Kim JH (2006) Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms. Drug Metab Dispos 34:1090–1095PubMedGoogle Scholar
  60. 60.
    Shou MG, Korzekwa KR, Crespi CL, Gonzalez FJ, Gelboin HV (1994) The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinog 10:159–168PubMedGoogle Scholar
  61. 61.
    Shou MG, Korzekwa KR, Krausz MS, Crespi CL, Gonzalez FJ, Gelboin HV (1994) Regioselective and stereoselective metabolism of phenanthrene by 12 cDNA-expressed human, rodent, and rabbit cytochromes P450. Cancer Lett 83:305–313PubMedGoogle Scholar
  62. 62.
    Yamazaki H, Mimura M, Oda Y, Gonzalez FJ, El Bayoumy K, Chae YH, Guengerich FP, Shimada T (1994) Activation of trans-1,2-dihydro-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. Carcinogenesis 15:465–470PubMedGoogle Scholar
  63. 63.
    Cho TM, Rose RL, Hodgson E (2006) In vitro metabolism of naphthalene by human microsomal cytochrome P450 enzymes. Drug Metab Dispos 34:176–183PubMedGoogle Scholar
  64. 64.
    Lewis DFV (1996) Cytochromes P450: structure, function, and mechanism. Taylor & Francis, LondonGoogle Scholar
  65. 65.
    Lewis DFV (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Toward the prediction of human P450 substrate specificity and metabolism. Biochem Pharmacol 60:293–306PubMedGoogle Scholar
  66. 66.
    Lewis DFV (2001) Guide to cytochromes P450: structure and function. Taylor & Francis, LondonGoogle Scholar
  67. 67.
    Guengerich FP (2005) Human cytochrome P450 enzymes. In: Otiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 3rd edn. Kluwer Academic/Plenum Publishers, New York, pp 377–530Google Scholar
  68. 68.
    Martignoni M, Groothuis GMM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894PubMedGoogle Scholar
  69. 69.
    Paine MF, Hart HL, Ludington SS, Haining RL, Retie AE, Zeldin DC (2006) The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–886PubMedCentralPubMedGoogle Scholar
  70. 70.
    Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111–121PubMedGoogle Scholar
  71. 71.
    Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Van den Branden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207–213PubMedGoogle Scholar
  72. 72.
    Shimada T, Yamazaki H, Mimura H, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423PubMedGoogle Scholar
  73. 73.
    Woldbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zamger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978–988Google Scholar
  74. 74.
    Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755–761PubMedGoogle Scholar
  75. 75.
    Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumara K, Honda G, Nakagawa K (2004) CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19:120–129PubMedGoogle Scholar
  76. 76.
    Wrighton SA, Ring BJ, Watkins RB, Van den Branden M (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 86:97–105Google Scholar
  77. 77.
    Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–891PubMedGoogle Scholar
  78. 78.
    Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31PubMedGoogle Scholar
  79. 79.
    Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023PubMedCentralPubMedGoogle Scholar
  80. 80.
    Lu C, Li AP (2001) Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague–Dawley rat, minipig, and beagle dog. Chem Biol Interact 134:271–281PubMedGoogle Scholar
  81. 81.
    Wang K, Chen S, Xie W, Wan YJY (2008) Retinoids induce cytochrome P450 3A4 through the RXR/VDR-mediated pathway. Biochem Pharmacol 75:2204–2213PubMedCentralPubMedGoogle Scholar
  82. 82.
    Woodland C, Huang TT, Gryz E, Bendayan R (2008) Expression, activity and regulation of CYP3A in human and rodent brain. Drug Metab Rev 40:149–168PubMedGoogle Scholar
  83. 83.
    Kliewer SA, Goodwin B, Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702PubMedGoogle Scholar
  84. 84.
    Burk O, Wojnowsk L (2004) Cytochrome 3A and their regulation, Naunyn-Schmiedeberg’s Arch. Pharmacology 369:105–124Google Scholar
  85. 85.
    Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brisen K (1999) In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289:31–37PubMedGoogle Scholar
  86. 86.
    Hrycay EG, Bandiera SM (2008) Cytochrome P450 enzymes. In: Gad SC (ed) Preclinical development handbook: ADME and biopharmaceutical properties. Wiley, Hoboken, pp 627–696Google Scholar
  87. 87.
    Christensen N, Mathiesen L, Postvoll LW, Winther B, Molden E (2009) Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources. Drug Metab Pharmacokinet 24:261–268PubMedGoogle Scholar
  88. 88.
    Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J (2009) Functional characterization of CYP3A4: catalytic activities toward midazolam and carbamazepine. Xenobiotica 39:140–147PubMedGoogle Scholar
  89. 89.
    Hrycay EG, Bandiera SM (2009) Expression, function and regulation of mouse cytochrome P450 enzymes: comparison with human cytochrome P450 enzymes. Curr Drug Metab 10:1151–1183PubMedGoogle Scholar
  90. 90.
    Yamazaki H, Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161–169PubMedGoogle Scholar
  91. 91.
    Feo ML, Gross MS, McGarrigle BP, Eljarrat E, Barcelo D, Aga DS, Olson JR (2013) Biotransformation of BDE-47 to potentially toxic metabolites is predominantly mediated by human CYP2B6. Environ Health Perspect 121:440–446PubMedCentralPubMedGoogle Scholar
  92. 92.
    Erratico CA, Szeitz A, Bandiera SM (2013) Biotransformation of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) by human liver microsomes: identification of cytochrome P450 2B6 as the major enzyme involved. Chem Res Toxicol 26:721–731PubMedGoogle Scholar
  93. 93.
    Alaee M, Arias P, Sjödin A, Bergman A (2003) An overview of commercially used brominated flame retardants, their applications, their use patterns in different countries/regions and possible mode of release. Environ Int 29:683–689PubMedGoogle Scholar
  94. 94.
    LaGuardia AMJ, Hale RC, Harvey E (2006) Detailed polybrominated diphenyl ether (PBDE) congener composition of the widely used penta-, octa-, and deca-PBDE technical flame-retardant mixtures. Environ Sci Technol 40:6247–6254Google Scholar
  95. 95.
    Hale RC, LaGuardia MJ, Harvey E, Mainor TM (2002) Potential role of fire retardant-treated polyurethane foam as a source of brominated diphenyl ethers to the US environment. Chemosphere 46:729–735PubMedGoogle Scholar
  96. 96.
    Hites RA (2004) Polybrominated diphenyl ethers in the environment and in people: a meta-analysis of concentration. Environ Sci Technol 38:945–956PubMedGoogle Scholar
  97. 97.
    Darnerud PO, Eriksen GS, Jóhannesson T, Larsen PB, Viluksela M (2001) Polybrominated diphenyl ethers: occurrence, dietary exposure, and toxicology. Environ Health Perspect 109:49–68PubMedCentralPubMedGoogle Scholar
  98. 98.
    Hale RC, La Guardia MJ, Harvey EP, Mainor TM, Duff MH, Gaylor MO (2001) Polybrominated diphenyl ether flame retardants in Virginia freshwater fishes (USA). Environ Sci Technol 35:4585–4591PubMedGoogle Scholar
  99. 99.
    Ikonomou M, Rayne S, Addison RF (2002) Exponential increase of brominated flame retardants, polybrominated diphenyl ethers, in the Canadian arctic from 1981 to 2000. Environ Sci Technol 36:1886–1892PubMedGoogle Scholar
  100. 100.
    Stapleton HM, Dodder NG, Offenberg JH, Schantz MM, Wise SA (2005) Polybrominated diphenyl ethers in house dust and clothes dryer lint. Environ Sci Technol 39:925–931PubMedGoogle Scholar
  101. 101.
    de Wit CA, Alaee M, Muir DCG (2006) Levels and trends of brominated flame retardants in the Arctic. Chemosphere 64:209–233PubMedGoogle Scholar
  102. 102.
    Gómara B, Herrero L, Ramos JJ, Mateo JR, Fernandez MA, Garcia JF, Gonzales MJ (2007) Distribution of polybrominated diphenyl ethers in human umbilical cord serum, paternal serum, maternal serum, placentas, and breast milk from Madrid population, Spain. Environ Sci Technol 41:6961–6968PubMedGoogle Scholar
  103. 103.
    Kelly BC, Ikonomou MG, Blair JD, Gobas FAPC (2008) Bioaccumulation behaviour of polybrominated diphenyl ethers (PBDEs) in a Canadian Arctic marine food web. Sci Total Environ 401:60–72PubMedGoogle Scholar
  104. 104.
    Vonderheide AP, Mueller KE, Meija J, Welsh L (2008) Polybrominated diphenyl ethers: causes of concern and knowledge gaps regarding environmental distribution, fate and toxicity. Sci Total Environ 400:425–436PubMedGoogle Scholar
  105. 105.
    Athanasiadou M, Cuadra SN, Marsh G, Bergman A, Jakobsson K (2008) Polybrominated diphenyl ethers (PBDEs) and bioaccumulative hydroxylated PBDE metabolites in young humans from Managua, Nicaragua. Environ Health Perspect 116:400–408PubMedCentralPubMedGoogle Scholar
  106. 106.
    Sjödin A, Wong L-Y, Jones RS, Park A, Zhang Y, Hodge C, Dipietro E, McClure C, Turner W, Needham LL, Patterson DG Jr (2008) Serum concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyl (PBB) in the United States population: 2003–2004. Environ Sci Technol 42:1377–1384PubMedGoogle Scholar
  107. 107.
    Stapleton HM, Sjödin A, Jones RS, Niehuser S, Zhang Y, Patterson DG (2008) Serum levels of polybrominated diphenyl ethers (PBDEs) and foam recyclers and carpet installers working in the United States. Environ Sci Technol 42:3453–3458PubMedGoogle Scholar
  108. 108.
    Daniels JL, Pan I-J, Jones R, Anderson S, Patterson DG Jr, Needham LL, Sjödin A (2010) Individual characteristics associated with PBDE levels in U.S. milk samples. Environ Health Perspect 118:155–160PubMedCentralPubMedGoogle Scholar
  109. 109.
    Örn U, Klasson-Wehler E (1998) Metabolism of 2,2′,4,4′-tetrabromodiphenyl ether in rat and mouse. Xenobiotica 28:199–211PubMedGoogle Scholar
  110. 110.
    Marsh G, Athanasiadou M, Athanassiadis XJ, Sandholm A (2006) Identification of hydroxylated metabolites in 2,2′,4,4′-tetrabromodiphenyl ether exposed rats. Chemosphere 63:690–697PubMedGoogle Scholar
  111. 111.
    Sanders JM, Chen LJ, Lebetkin EH, Burka LT (2006) Metabolism and disposition of 2,2′,4,4′- tetrabromodiphenyl ether following administration of single or multiple doses to rats and mice. Xenobiotica 36:103–117PubMedGoogle Scholar
  112. 112.
    Staskal DF, Hakk H, Bauer D, Diliberto JJ, Birnbaum LS (2006) Toxicokinetics of polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. Toxicol Sci 94:28–37PubMedGoogle Scholar
  113. 113.
    Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Visser TJ, Van Velzen MJ, Brouwer A, Bergman A (2008) Biotransformation of brominated flame retardants into potentially endocrine-disrupting metabolites, with special attention to 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47). Mol Nutr Food Res 52:284–298PubMedGoogle Scholar
  114. 114.
    Erratico CA, Moffatt SC, Bandiera SM (2011) Comparative oxidative metabolism of BDE-47 and BDE-99 by rat liver microsomes. Toxicol Sci 123:37–47PubMedGoogle Scholar
  115. 115.
    Lupton SJ, McGarrigle BP, Olson JR, Wood TD, Aga DS (2009) Human liver microsome-mediated metabolism of brominated diphenyl ethers 47, 99, and 153 and identification of their major metabolites. Chem Res Toxicol 22:1802–1809PubMedGoogle Scholar
  116. 116.
    Lupton SJ, McGarrigle BP, Olson JR, Wood TD, Aga DS (2010) Analysis of hydroxylated polybrominated diphenyl ether metabolites by liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 24:2227–2235PubMedGoogle Scholar
  117. 117.
    Marteau C, Chevolleau S, Jouanin I, Perdu E, De Sousa G, Rahmani R, Antignac JP, LeBizec B, Zalko D, Debrauwer L (2012) Development of a liquid chromatography/atmospheric pressure photo-ionization high resolution mass spectrometry analytical method for the simultaneous determination of polybrominated diphenyl ethers and their metabolites: application to BDE-47 metabolism in human hepatocytes. Rapid Commun Mass Spectrom 26:599–610PubMedGoogle Scholar
  118. 118.
    Moffatt S, Edwards PR, Szeitz A, Bandiera SM (2011) A validated liquid chromatography-mass spectrometry method for the detection and quantification of oxidative metabolites of 2,2′,4,4′-tetrabromodiphenyl ether in rat hepatic microsomes. Am J Anal Chem 2:352–362Google Scholar
  119. 119.
    Erratico CA, Szeitz A, Bandiera SM (2010) Validation of a novel in vitro assay using ultra performance liquid chromatography-mass spectrometry (UPLC/MS) to detect and quantify hydroxylated metabolites of BDE-99 in rat liver microsomes. J Chromatogr B 878:1562–1568Google Scholar
  120. 120.
    Korzekwa KR, Swinney DC, Trager WT (1989) Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. Biochemistry 28:9019–9027PubMedGoogle Scholar
  121. 121.
    de Visser S, Shaik S (2003) A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome P450 enzymes. J Am Chem Soc 125:7413–7424PubMedGoogle Scholar
  122. 122.
    Erratico CA, Szeitz A, Bandiera SM (2012) Oxidative metabolism of BDE-99 by human liver microsomes: predominant role of CYP2B6. Toxicol Sci 129:280–292PubMedGoogle Scholar
  123. 123.
    Ortiz de Montellano PR (1995) Oxygen activation and reactivity. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 2nd edn. Plenum Press, New York, pp 245–304Google Scholar
  124. 124.
    Deo AK, Bandiera SM (2009) 3-Ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid. Drug Metab Dispos 37:1938–1947PubMedGoogle Scholar
  125. 125.
    Chiang JY (2004) Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40:539–551PubMedGoogle Scholar
  126. 126.
    Makishima M (2005) Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 97:177–183PubMedGoogle Scholar
  127. 127.
    Kalaany NK, Mangelsdorf DJ (2006) LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159–191PubMedGoogle Scholar
  128. 128.
    Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50:1955–1966PubMedCentralPubMedGoogle Scholar
  129. 129.
    Nguyen A, Bouscarel B (2008) Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 20:2180–2197PubMedGoogle Scholar
  130. 130.
    Fiorucci S, Mencarelli A, Palladino G, Cipriani S (2009) Bile acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30:570–580PubMedGoogle Scholar
  131. 131.
    Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P (2009) Bile acids as regulatory molecules. J Lipid Res 50:1509–1520PubMedCentralPubMedGoogle Scholar
  132. 132.
    Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89:147–191PubMedGoogle Scholar
  133. 133.
    Hofmann AF (1999) Bile acids: the good, the bad, and the ugly. News Physiol Sci 14:24–29PubMedGoogle Scholar
  134. 134.
    Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647–2658PubMedGoogle Scholar
  135. 135.
    Hofmann AF, Hagey LR (2008) Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65:2461–2483PubMedGoogle Scholar
  136. 136.
    Dawson PA, Schneider BL, Hofmann AF (2006) Bile formation and the enterohepatic circulation. In: Johnson LR (ed) Physiology of the gastrointestinal tract, vol 1, 4th edn. Academic, New York, pp 1437–1462Google Scholar
  137. 137.
    Small DM (2003) Role of ABC transporters in secretion of cholesterol from liver into bile. Proc Natl Acad Sci U S A 100:4–6PubMedCentralPubMedGoogle Scholar
  138. 138.
    Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592PubMedGoogle Scholar
  139. 139.
    Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter DL, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to complete absence of phospholipid from bile and to liver disease. Cell 75:451–462PubMedGoogle Scholar
  140. 140.
    Lehman-McKeeman LD (2008) Absorption, distribution, and excretion of toxicants. In: Klaassen CD (ed) Casarett & Doull’s toxicology: the basic science of poisons, 7th edn. McGraw Hill, Toronto, pp 131–159Google Scholar
  141. 141.
    Leuschner U (2009) Formation and secretion of bile and bilirubin metabolism. In: Dancygier H (ed) Clinical hepatology: principles and practice of hepatobiliary diseases, vol 1. Springer, Berlin, pp 103–126Google Scholar
  142. 142.
    Grober J, Zaghini I, Fujii H, Jones SA, Kliewer SA, Willson TM, Ono T, Besnard P (1999) Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 274:29749–29754PubMedGoogle Scholar
  143. 143.
    Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362–1365PubMedGoogle Scholar
  144. 144.
    Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731–744PubMedGoogle Scholar
  145. 145.
    Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48:2664–2672PubMedGoogle Scholar
  146. 146.
    Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369–3374PubMedCentralPubMedGoogle Scholar
  147. 147.
    Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313–1316PubMedGoogle Scholar
  148. 148.
    Hofmann AF (2002) Cholestatic liver disease: pathophysiology and therapeutic options. Liver 22(Suppl 2):14–19Google Scholar
  149. 149.
    Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259PubMedGoogle Scholar
  150. 150.
    Setchell KD, Rodrigues CM, Clerici C, Solinas A, Morelli A, Gartung C, Boyer J (1997) Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112:226–235PubMedGoogle Scholar
  151. 151.
    Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M (2006) Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 168:410–522PubMedCentralPubMedGoogle Scholar
  152. 152.
    Beilke LD, Besselsen DG, Cheng Q, Kulkarni S, Slitt AL, Cherrington NJ (2008) Mininal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis. Toxicol Sci 102:196–204PubMedGoogle Scholar
  153. 153.
    Deo AK, Bandiera SM (2008) Biotransformation of lithocholic acid by rat hepatic microsomes: metabolite analysis by liquid chromatography/mass spectrometry. Drug Metab Dispos 36:442–451PubMedGoogle Scholar
  154. 154.
    Wood AW, Swinney DC, Thomas PE, Ryan DE, Hall PF, Levin W, Garland WA (1988) Mechanism of androstenedione formation from testosterone and epitestosterone catalyzed by purified cytochrome P-450b. J Biol Chem 263:17322–17332PubMedGoogle Scholar
  155. 155.
    Swinney DC, Ryan DE, Thomas PE, Levin W (1988) Evidence for concerted kinetic oxidation of progesterone by purified rat hepatic cytochrome P-450 g. Biochemistry 27:5461–5470PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Claudio A. Erratico
    • 1
    • 2
  • Anand K. Deo
    • 1
    • 3
  • Stelvio M. Bandiera
    • 1
    Email author
  1. 1.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada
  2. 2.Toxicology CenterUniversity of AntwerpWilrijkBelgium
  3. 3.UCB PharmaBriane l’AlleudBelgium

Personalised recommendations